相关实验视频

Updated: Jan 16, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

转移性前列腺癌患者的基因驱动,强度调节的适应性管理

Reynier D Rodriguez Rosales¹, Arjun Venkatesh¹, Jean-Pierre Kanumuambidi¹

¹Department of Urology, University of Florida College of Medicine - Jacksonville, Jacksonville, Florida, USA.

|October 5, 2025

概括

特定基因集群中的基因组变化,主要是淋巴结性转移性前列腺癌 (mPC),解释了生存差异. 这些发现可以指导加强后续和新型组合疗法.

科学领域:

在瘤学瘤学.
基因组学就是基因组学.
癌症研究癌症研究

背景情况:

患有转移性前列腺癌 (mPC) 的男性的生存结果根据转移部位 (淋巴结与骨) 显著不同.
了解这种差异的基因组基础对于个性化治疗和后续策略至关重要.

研究的目的:

调查特定位点的基因组变化及其组合是否解释了男性mPC的生存差距.
识别基因组特征,这些特征可以为强度调节后续或治疗干预提供信息.

主要方法:

使用cBioPortal注册表对1011名mPC男性的临床和向测序数据进行分析.
评估单个基因和多基因集群与整体存活率 (OS) 的关联,使用卡普兰-梅尔曲线和dRMST识别显著差异.
使用SLOAD数据库探索合成-致命 (SL) 相互作用.

主要成果:

在184个分析的基因中,有18个 (9.8%) 呈现出显著的变异. 在骨或淋巴结转移中,特定的基因被丰富.
65个多基因集群与劣质的OS相关,主要在淋巴结单独mPC亚组中.
高风险集群预测OS分歧10-60个月后转移诊断;确定了615个假定的SL对.

结论:

特定于位点的多基因集群,特别是在淋巴结mPC中,是结节和骨转移之间的生存差异的基础.
鉴定的基因组签名表明,强度调节后续的10-60个月窗口.
数以百计的合成-致命基因改变对为未来的组合治疗策略提供了潜在的mPC.

关键词:

遗传变化遗传变化转移性疾病的转移性疾病下一代测序是下一代的测序.前列腺癌是前列腺癌.瘤热带性瘤热带性

更多相关视频

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...